Clearance

Zacks Small Cap Research – MGRM: The De-Risking of the Monogram Story from FDA Clearance and Initiation of Live Patient Trials Supports Price Target of $6.00 – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 1st quarter 2025 financial results on May 14, 2025 which were largely in line with our expectations. Research and development expenses for the quarter were $2.26 million compared to $2.41 million in the prior year period. The R&D decrease was primarily … Read more

Zacks Small Cap Research – MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT On March 17, 2025, Monogram (NASDAQ:MGRM) announced that the FDA has granted 510(k) clearance for its Monogram mBôs TKA System. This determination means that the company can move forward with upgrades and begin the commercialization process. The mBôs TKA System is designed to deliver … Read more